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The naturally occurring antagonist of interleukin-1, IL-1RA, is highly neuroprotective experimentally,
shows few adverse effects, and inhibits the systemic acute phase response to stroke. A single
regime pilot study showed slow penetration into cerebrospinal fluid (CSF) at experimentally
therapeutic concentrations. Twenty-five patients with subarachnoid hemorrhage (SAH) and external
ventricular drains were sequentially allocated to five administration regimes, using intravenous
bolus doses of 100 to 500mg and 4hours intravenous infusions of IL-1RA ranging from 1 to 10mg
per kg per hour. Choice of regimes and timing of plasma and CSF sampling was informed by
pharmacometric analysis of pilot study data. Data were analyzed using nonlinear mixed effects
modeling. Plasma and CSF concentrations of IL-1RA in all regimes were within the predicted
intervals. A 500-mg bolus followed by an intravenous infusion of IL-1RA at 10mg per kg per
hour achieved experimentally therapeutic CSF concentrations of IL-1RA within 45minutes.
Experimentally, neuroprotective CSF concentrations in patients with SAH can be safely achieved
within a therapeutic time window. Pharmacokinetic analysis suggests that IL-1RA transport across
the blood–CSF barrier in SAH is passive. Identification of the practicality of this delivery regime
allows further studies of efficacy of IL-1RA in acute cerebrovascular disease.
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Introduction
Cerebral ischemia in stroke and subarachnoid hemor-
rhage (SAH) is a major cause of death and disability
(Rabinstein et al, 2004). Although there have been in
excess of 110 trials of potentially neuroprotective
drugs (O’Collins et al, 2006), few have shown
promising results and only one, recombinant tissue
plasminogen activator, is currently licensed for
administration. The use of recombinant tissue plas-
minogen activator is limited to within 4.5hours of
stroke after the onset of symptoms and requires that
the criteria for patients with ischemic stroke who
could be treated with recombinant tissue plasmino-
gen activator are fully satisfied (Adams et al, 2007).
Although the proportion of patients arriving to
hospital with 4.5hours of stroke onset is B30%
(Deng et al, 2006), recombinant tissue plasminogen
activator is administered to only 6% to 25% for a
variety of reasons (Huang et al, 2006b). Apart from
the use of calcium channel blocker nimodipine in
SAH (Dorhout Mees et al, 2007), no pharmacological
agent has been proven to improve outcome in
hemorrhagic stroke, intracerebral hemorrhage, or
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tration of nimodipine occasionally limit its use
(Topcuoglu and Singhal, 2006).
There is an increasing body of evidence to suggest
that inflammation has an important function in
the pathological events arising as a consequence
of cerebral ischemia (Huang et al, 2006a) and that
the proinflammatory cytokine interleukin-1 (IL-1) is
particularly implicated as an important mediator
(Boutin et al, 2001; Buttini et al, 1994; Hara et al,
1997; Yamasaki et al, 1995). The IL-1RA is the
naturally occurring antagonist of IL-1 and is the most
widely studied putative neuroprotective agent in
acute cerebrovascular disease (Banwell et al, 2009).
It is a potent inhibitor of experimentally induced
ischemic brain damage when given intracerebro-
ventricularly (Loddick and Rothwell, 1996), intra-
peritoneally (Ohtsuki et al, 1996), intravenously
(Clark et al, 2008), and subcutaneously (Relton
et al, 1996) up to 3 hours after induction of ischemia
(Mulcahy et al, 2003). A recombinant formulation
of IL-1RA, anakinra (Kineret) (Amgen Inc, Thousand
Oaks, CA, USA) is manufactured and licensed as a
secondary-line treatment for rheumatoid arthritis.
Clinically, it is effective in reducing peripheral
markers of inflammation in stroke (Emsley et al,
2005) and has been shown to have a good safety and
tolerability profile in SAH (Clark et al, 2008), stroke
(Emsley et al, 2005), and other diseases such as
rheumatoid arthritis (Nuki et al, 2002) and diabetes
mellitus (Larsen et al, 2007). In SAH, IL-1 potentially
contributes to the development of cerebral ischemia
through various mechanisms. It may cause vasospasm
by the upregulation of potent vasoconstrictors such as
endothelin and induction of IL-6 that has been shown
to induce vasospasm in experimental studies. The
IL-1 contributes to blood–brain barrier (BBB) dysfunc-
tion, worsens cerebral edema, and leads to increased
intracranial pressure (Blamire et al,2 0 0 0 ) .I tm a y
enhance cytotoxicity caused by NMDA-mediated
cortical spreading depression, another potential cause
of delayed cerebral ischemia after SAH (Obrenovitch
and Zilkha, 1996). The IL-1 may also be a primary
driver of a systemic acute phase response, including
an increase in plasma IL-6 (McMahon et al, 2010).
Finally, it acts as an endothelial activator and is
induced during the coagulation cascade triggered
by tissue injury (Cicala and Cirino, 1998).
Studying the pharmacokinetics of IL-1RA is
pivotal to the process of development of the drug
as a potential neuroprotective agent, is a prerequi-
site for pharmacodynamic studies and one of the
main Stroke Therapy Academic Industry Roundtable
(STAIR) criteria drafted in effort to maximize the
potential success of any potential stroke treatment
(STAIR, 2001). Investigating the pharmacokinetics of
IL-1RA within the central nervous system is techni-
cally challenging in stroke given the lack of access
to both CSF and intraparenchymal tissue. The SAH
patients who undergo insertion of an external
ventricular drain (EVD) to control intracranial
pressure provide ready access to CSF and therefore
present an ideal cohort in which to investigate IL-
1RA pharmacokinetics across the BBB. The BBB
integrity influences the transfer of IL-1RA across the
BBB and there is inter- and intracondition hetero-
geneity in the extent of BBB disruption. Radiological
evidence of BBB disruption is present in stroke
patients, cerebral small vessel disease, and lacunar
stroke (Topakian et al, 2010). In poor-grade SAH,
contrast-enhanced computed tomography and iso-
tope brain scintigraphy studies have also shown that
there is widespread BBB dysfunction (Doczi, 1985).
Moreover, in SAH patients who experience overt
delayed cerebral ischemia (DCI) leading to cerebral
infarction, the extent of BBB dysfunction within the
infarct would be expected to be similar to that in
primary acute stroke affecting the same vascular
distribution.
In preclinical studies, a cerebrospinal fluid (CSF)
concentration of 100ng/mL of IL-1RA within 1hour
of transient middle cerebral artery ischemia was
observed to correspond to its neuroprotective effect
(Clark et al, 2008). A pilot study in SAH patients
showed that intravenous IL-1RA given as a bolus of
100mg followed by an infusion of 2mg per kg per
hour was safe and penetrated the BBB to achieve
this experimentally therapeutic concentration within
3 hours of commencement of infusion (Clark et al,
2008). Given that an average of 1.9 million neurones
are destroyed per minute (Saver, 2006), and the delay
from onset of symptoms to commencement of drug
administration (Lacy et al, 2001), it is essential
that therapeutic concentrations are achieved within
the shortest time possible. We therefore set out to
identify a safe, tolerable, practical administration
regime that could achieve experimentally thera-
peutic CSF concentrations of IL-1RA within a
reasonable time window.
Materials and methods
The study protocol was submitted and approved by
Amgen Inc who provided the drug, anakinra, free of
charge. Medicine and Healthcare Products Regulatory
Agency and National Research Ethics Committee approvals
were obtained before the study commenced.
Patient Recruitment
Eighty-eight patients were screened and 30 were recruited
from the Intensive Care and High Dependency units at
Salford Royal NHS Foundation Trust, UK and Cambridge
University Hospitals NHS Foundation Trust, UK between
December 2007 and December 2008 (Figure 1). Patients
were Caucasian, aged 37 to 76 years (mean age=53 years),
with a mean weight of 73kg (range, 58 to 110kg). Patients
eligible for the study had radiologically confirmed SAH
and an external ventricular drain inserted to manage
ensuing hydrocephalus. Exclusion criteria for study
entry included a clinically significant concurrent medical
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or concurrent immunosuppressant medication. Pregnant or
breast-feeding patients, those with a history of sensitivity to
products derived from Escherichia coli and patients suffer-
ing from malignancies were also excluded.
Written consent was obtained from the next of kin for
all patients as none were deemed fit to consent at the time
of recruitment. Two patients improved cognitively during
the course of the study and were subsequently approached
for consent. Four patients recruited into the study did
not receive the investigational medicinal product for
various reasons including accidental removal of the
EVD and death. Of the 25 patients receiving the drug,
22 were recruited from Salford and 3 from Cambridge.
General patient characteristics are shown in Table 1.
Clinical history and demographic data were collected
and a physical examination was performed on each
patient. At presentation, 17 patients were poor grade
(World Federation of Neurosurgeons Score IV and V) and
8 were good grade (World Federation of Neurosurgeons
Score I–III). The distribution of blood on computed tomo-
graphy scan varied but all had diffuse clots of blood (Fisher
grade III) or intraventricular blood (Fisher grade IV). Of
the 25 patients receiving the investigational medicinal
product, 20 had solitary aneurysms and 5 had multiple
aneurysms. In all, 76% of the aneurysms were located
within the anterior circulation and the majority (21) were
coiled.
Pharmacokinetics
An empirical pharmacokinetic (PK) model for intravenous
anakinra has already been published by our research group
(Gueorguieva et al, 2008), with population pharmacokinetics
(PPK) fitting a linear two-compartment model for plasma
with elimination from the central compartment and a one-
compartment model for CSF. Before using this model to
inform the design of our dose-ranging study, the raw data for
the model-making study were reviewed and the parameter
estimates for the published model were refined using the
NONMEM computer program, version VI (ICON Develop-
ment Solutions, Dublin, Ireland).
Using revised parameter estimates, simulation of different
permutations of intravenous boluses (ranging from 100 to
1000mg in 100mg steps) and infusions (ranging from 1 to
10mg per kg per hour for 4hours in 1mg per kg per hour
steps) of anakinra were performed. Simulations were
performed using a custom script in GNU-R. The adminis-
tration regime that would potentially achieve our target
CSF concentration within 30minutes of start of infusion of
IL-1RA with the lowest peak plasma concentration (Cmax)
was determined to be 500mg intravenous bolus followed by
an intravenous infusion of 10mg per kg per hour. Although
our initial aim was 60minutes, we have chosen 30minutes
to safeguard against possible deviations of actual from
predicted CSF concentration profiles of anakinra. For safety
reasons, four other regimes were chosen, each reflecting
a stepwise increase in Cmax (Table 2).
The published PPK model was based on a single-dose
regime using a much lower bolus dose and infusion rates
of intravenous IL-1RA. Given that earlier experimental
data had indicated that the IL-1 family (IL-1a, IL-1b, and
IL-1RA) is transported through a saturable mechanism
across the BBB (Banks et al, 1991; Gutierrez et al, 1994),
it was important to determine whether data generated
during this study would match the concentrations profiles
predicted by the model. Prediction intervals for plasma
and CSF for each of the administration regimes were
therefore calculated. To further optimize the efficacy and
reduce the risk of introducing central nervous system
infection by unnecessary repeated sampling, the optimal
sampling time points for plasma and CSF were determined
by pharmacometric analysis using published techniques
(Ogungbenro et al, 2005).
Patients received anakinra within a mean of 4 days
(range, 2 to 12 days) from ictus. Baseline blood and CSF
samples were obtained within 5minutes before anakinra
administration for measurement of IL-1RA concentrations
and determination of preinfusion biochemical and hemato-
logical profiles. Participants were administered a bolus
Total screened
88 (59, 29)
Recruited
29 (23, 6)
Not recruited
59 (36, 23)
IMP administered
25 (22, 3)
IMP not administered
4 (1, 3)
30 minute sample obtained
25 (22, 3)
Consistent data set
22 (22, 0)
Inconsistent data set
3 (0, 3)
Figure 1 Screening and recruitment schema (black=SRFT,
gray=Cambridge). IMP , investigational medicinal product.
Table 1 General patient characteristics for patients receiving
anakinra
Male:female ratio 7:18
Smokers 64%
Hypertensive (diagnosed preictus) 24%
Ethnicity 100% Caucasian
Weight (mean, range) 73.4kg (58–110kg)
Right handed 100%
IL-1RA enters central nervous system within a therapeutic time window
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line that was immediately followed by a continuous
infusion of anakinra diluted in 500mL of clinical grade
0.9% saline over 4 hours through a volumetric pump
(Graseby, Watford, UK). Five patients were allocated to
each of the five regimes sequentially.
Samples of up to 3mL of CSF and up to 5mL of blood
were obtained using a sterile nontouch technique after
removal and discard of B2mL of CSF or blood. At 10, 20,
30, 45, 60, 90, 120, 240, 300, 360, 540minutes and at days
1, 2, 3, and 7±1, CSF and plasma samples were collected
in EDTA and anticoagulant-free tubes, respectively, and
kept at 01Ct o4 1C. Samples were centrifuged at 2000g
and 41C for 15minutes. Plasma and CSF were decanted
into 2mL freeze vials and stored at 701C until analysis.
The IL-1RA assays were performed using an ‘in-house’
immunoassay, calibrated against National Institute for
Biological Standards Control (South Mimms, UK) stan-
dards, as described earlier (Emsley et al, 2005). The
technicians were masked to the infusion rate.
The occurrence of adverse events was monitored by the
research team. Full clinical examinations were performed
at days 1, 2, 3, and 7±1 after infusion. Hematological,
biochemical, and microbiological results were monitored
on a daily basis until day 7 after commencement of
infusion. The CSF was sent for microscopy, culture and
antibiotic sensitivity whenever sampled for research
purposes. The EVD infections were defined as the presence
of a ratio of white cells: red blood cells of >500 in the
CSF or the presence of organisms in two consecutive
CSF samples. They were documented as being expected
if the drains had been in situ for longer than 10 days, if
there had been a documented significant CSF leak around
the exit site or if there had been a documented breach of
sterility of the drainage systems before investigational
medicinal product was administered. All adverse events
were classified and logged into the case-report forms and
reported to the study sponsor and the Independent Data
Monitoring and Safety Committee for review. Interim
analyses of these adverse events were performed after each
regime to review data quality and safety before proceeding
to the next dose regime.
Concentration profiles of anakinra in plasma and CSF
were analyzed to ensure that they did fit within prediction
intervals calculated a priori. Safety data were analyzed
descriptively. Nonlinear mixed effects modeling using
NONMEM version IV was used to remodel the cumulative
data obtained to date on PK of intravenous administered
anakinra in patients with SAH. Student’s t-test using SPSS
version 16 (SPSS Inc, Chicago, IL, USA) was used to
investigate the effect of anakinra administration on
neutrophil count, temperature, and creatinine. General
linear mixed model analysis was used to analyze the
possible effect of covariates including dose regime used
and time since administration on these variables. The
half-life of anakinra was calculated using the formula
t1
2=0.693/k, where k is the first-order elimination constant.
Simulation and graphical representation of the data
were performed using GNU-R, Matlab version 2008a
(MathWorks, Natick, MA, USA) and CorelDraw X4 (Corel
Corp, Ottawa, ON, Canada). Area under the curve analysis
was performed using Graphpad Prism Software (Graphpad,
San Diego, CA, USA).
Results
Safety
All patients completed the 4-hour infusion of
anakinra. Pharmacokinetic data for CSF for the three
patients recruited from Cambridge had to be omitted
because of contamination with plasma resulting in
aberrant IL-1RA concentrations. There were four
deaths during the 7-day study period and all of
these were related to cerebral ischemia. One of these
patients had demonstrable absence of filling of the
ipsilateral middle cerebral artery at the time of initial
angiography before commencing the infusion.
The infection rate for EVDs was 3/25 or 12%, with
two of these being expected. An independent audit
performed by the neurosurgical department during
the same period showed an overall infection rate for
EVDs in the neurosurgical unit of 20%. The complete
list of adverse events is listed in Table 3. All adverse
events were reported to the Independent Data
Monitoring and Safety Committee but none were
deemed attributable to the study drug.
Effect of Hematological and Biochemical Parameters
There was a statistically significant reduction in
neutrophil counts between before administration
and day 1 after administration of anakinra (t-test,
P=0.04) (Figure 2). None of the patients experienced
neutropenia. There was no significant difference
Table 2 Summary of proposed treatment regimes including estimated peak plasma concentrations and estimated times to reach
100ng/mL in the CSF
Regime no. Bolus (mg) Infusion
rate (mg/h)
Mean predicted peak
plasma concentration (ng/mL)
Total dose
(mg)
Estimated time taken to reach
100ng/mL of IL-1RA in CSF (minutes)
1 100 4 34,772 1220 104
2 200 2 41,152 760 141
3 300 2 61,728 860 96
4 400 6 82,304 2080 43
5 500 10 102,880 3300 30
CSF, cerebrospinal fluid; IL, interleukin.
IL-1RA enters central nervous system within a therapeutic time window
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regimes. For the duration of the study, anakinra had
no significant effect on hemoglobin concentration or
platelet numbers. In addition, there was no signi-
ficant alteration in biochemical, renal, or hepatic
parameters related to infusion of anakinra and no
effect on heart rate, blood pressure, or brain
temperature during the course of the study.
Pharmacokinetics of Anakinra
All IL-1RA plasma concentrations from the five
regimes fitted the prediction intervals that were
calculated a priori (see Figure 3). The IL-1RA CSF
concentrations for all patients except for those
recruited in Cambridge (patients 2, 4, and 5) also
fitted the prediction intervals. The mean baseline
concentration of IL-1RAwas 476pg/mL (±664pg/mL).
The concentration of IL-1RA in plasma after infusion
increased to peak values within the first 10 minutes
reflecting the predictable importance of the bolus dose
to achieve early high concentrations. After cessation
of intravenous infusion, concentrations in plasma
decreased rapidly with a half-life of 33minutes
(±9minutes) (see Figure 4).
The mean baseline concentration of IL-1RA in
CSF was 606pg/mL (±1300pg/mL). The concen-
tration of IL-1RA in CSF after intravenous infusion
of anakinra increased slowly over the 4-hour period
and continued to rise for a variable period beyond
the cessation of infusion. Steady state concentrations
were not reached. Concentrations in CSF decreased
slowly with an initial half-life of 238minutes for
regime 5. Area under the curve analysis for each of
the regimes comparing plasma and CSF concen-
trations showed that 1.6% (±0.4%) of intravenous
administered anakinra crossed into the CSF of
patients with SAH. There was no relationship
between the administration regime and amount of
IL-1RA entry into CSF.
The cumulative pharmacokinetic data from
the model-making study and the current study fit
a two-compartment and a one-compartment
linear model for plasma and CSF, respectively. The
IL-1RA concentration achieved in CSF in regime
5 at 30minutes was 70,403±23,417pg/mL and at
60minutes was 135,909±45,963pg/mL. The concen-
trations observed at 30minutes were less than those
predicted. Simulations using this updated PPK
model would suggest that a regime consisting of
an intravenous bolus of 1g of anakinra followed by
10mg per kg per hour would potentially achieve
100ng/mL of anakinra in CSF within 30minutes.
Studies investigating penetration of IL-1RA past
the BBB have been performed in rodent models using
radiolabeled substrates (Banks et al, 1991; Gutierrez
et al, 1994). These studies have shown that the
transport mechanism is saturable by virtue of varying
degrees of mutual cross-inhibition of entry of IL-1a,
IL-1b, and IL-1RA across the BBB. The percentage
transfer of IL-1RA across the blood–CSF barrier
in our study ranged from 0.97% to 1.27% and did
not differ significantly in our five regimes, suggesting
that transport of IL-1RA using administration regimes
up to 500mg bolus and 10mg per kg per hour is
largely passive.
Discussion
This dose-ranging study has determined the optimal
dose regime required to safely achieve an experi-
mentally therapeutic IL-1RA concentration in CSF
within a time window that would be appropriate for
the treatment of acute cerebral ischemia. This regime
has been identified as an intravenous bolus of 500mg
administered over a minute followed by intravenous
infusion of 10mg per kg per hour. The study has also
explored the effects of altering the bolus dose and the
infusion rate on the time to reach steady state and
Table 3 List of adverse events reported to the IDMSC during the
study
Category Adverse event n
Infection Chest infection 9
CSF infection 3
Gastroenteritis 1
PUO 3
UTI 2
Cerebrovascular Spasm/DCI 4
CSF drainage EVD malfunction 3
MODS 1
Arrhythmia 2
Rectal prolapse 1
Total 29
CSF, cerebrospinal fluid; DCI, delayed cerebral ischemia; EVD, external
ventricular drain; IDMSC, Independent Data Monitoring and Safety Committee;
MODS, multiple organ dysfunction syndrome; PUO, pyrexia of unknown
origin; UTI, urinary tract infection.
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Figure 2 Neutrophil count pre and days 1, 2, 3, and 7 after
administration of anakinra (*P<0.05).
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model.
Anakinra has an excellent safety and tolerability
profile in the subcutaneous formulation that is cur-
rently licensed for use in rheumatoid arthritis and
has been used in clinical trials for type 2 diabetes
(Larsen et al, 2007), juvenile arthritis (Ilowite et al,
2009), Muckle Wells syndrome (Hawkins et al, 2004),
Schnitzler’s syndrome (Schneider et al, 2007), and
non-ST segment myocardial infarction. Concerns
over the potential risk of infection have occasionally
arisen given the slight increase (2% in anakinra
patients versus <1% in placebo) in rheumatoid
arthritis patients (Nuki et al, 2002). This increase in
infection rate occurred in the context of long-term
administration in patients that were on a variety
of immune-modulating drugs such as steroids
and methotrexate. The intravenous formulation has
already been trialled in studies of patients with acute
sepsis without any safety concerns and the adminis-
tration regime used had already been used by our
group in the model-making study in SAH patients. In
this study, however, the infusion rate and Cmax was
much higher. Recruitment was temporarily ceased
after the first two regimes and after each subsequent
regime to allow the Independent Data Monitoring
and Safety Committee time to review and analyze
the adverse events before progressing to higher
dose regimes. There was, however, no suspected
unexpected serious adverse reactions and none
of the adverse events could be attributed to anakinra.
The incidence of EVD infections was less than that
generally experienced in other neurosurgical units
(Arabi et al, 2005). This could be attributed to the
meticulous sterile approach adopted, as opposed to
the standard aseptic nontouch technique that is
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Figure 3 Predicted plasma (red lines) and cerebrospinal fluid (CSF) (blue lines) mean and interval concentration profiles, and actual
plasma (red points) and CSF (blue points) for each regime. IL, interleukin.
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of anakinra itself. Similarly, although the occurrence
of chest infections is commonplace in poor-grade SAH
because of the high incidence of aspirations of gastric
contents during the ictus of the bleed, our rate of
respiratory infections were similar to or lower than
that reported in similar studies (Berrouane et al, 1998).
The mortality in our study (16%) compared favorably
with published studies (Seifert et al, 1990).
Plasma concentrations of IL-1RA after intravenous
anakinra administration were predicted very accu-
rately by our previously published model and the
deviation from the mean individual predicted values
was low. Although CSF concentrations during the
infusion and immediate postinfusion period of most
patients did fit within the 2.5% to 97.5% prediction
intervals, the spread around the mean individual
predicted profile was much larger. This was a
reflection of the relatively unconstrained nature of
the original model equation predicting CSF concen-
trations. The CSF concentrations in the later phase
(terminal half-life period) varied considerably. At
such low concentrations, the endogenous production
of IL-1RA significantly affects the overall (endogen-
ous IL-1RA and anakinra) IL-1RA concentrations and
probably accounts for moderate deviations from the
predicted mean. The CSF infection, inflammation
from mechanical irritation of brain parenchyma, and
possibly inflammation as a response to delayed
cerebral ischemia may account for elevated endo-
genous concentrations of IL-1RA.
A key question governing the pharmacokinetics of
IL-1RA that could affect the applicability of our PPK
data to patients with good grade SAH and patients
with other forms of acute cerebrovascular disease is
the degree of breakdown of compartmentalization of
inflammation. We are aware that our patient cohort may
not be representative of the general population suffering
from SAH given those patients who require EVDs tend
to represent the poorer grades, have more brain edema
and may consequently exhibit a leakier BBB and blood–
CSF barrier. Similarly, it may be debatable whether the
pharmacokinetics of anakinra in this subpopulation of
SAH patients is similar in other acute cerebrovascular
disease states. It is, however, exceedingly difficult to
gain repeated access to CSF in diseases such as stroke,
as this can precipitate incipient tonsillar brain hernia-
tion, is not warranted for clinical reasons, and may
cause unnecessary patient distress.
Another dilemma that may affect the validity of
our study is the likely site of action of IL-1RA. If the
main mode of action of IL-1RA is within the BBB,
brain extracellular fluid concentrations associated
with experimental neuroprotection may be more
important than CSF concentrations. In the absence
of reliable mechanisms of detecting concentrations of
anakinra within extracellular fluid (unpublished
studies using microdialysis of IL-1RA in vitro showed
recovery to be very unreliable), CSF is the only
measure of brain penetration available. Moreover,
the intracerebroventricularly route of administration
was the most effective in experimental studies.
In contrast to other failed neuroprotective agents
for which penetration into the site of action was not
shown, there is now significant evidence that IL-1RA
enters CSF and that the rate at which this occurs can
be safely modulated by altering the administration
regime. A functional PPK model for anakinra has
potential significant clinical therapeutic implica-
tions. If IL-1RA is proven to be neuroprotective and
its efficacy is maximal within a certain therapeutic
time window, administration of the drug may be
individually tailored to patients to ensure maximal
efficacy. Phase II efficacy studies informed by safety
and PPK data from this study are currently under
way. We believe that our approach may be widely
applicable to the evaluation of other pharmacological
therapeutic strategies targeting mechanisms within
the central nervous system.
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Figure 4 Mean plasma (A) and cerebrospinal fluid (CSF) (B)
interleukin (IL)-1RA concentrations for patients in regimes 1–5.
IL-1RA enters central nervous system within a therapeutic time window
J Galea et al
445
Journal of Cerebral Blood Flow & Metabolism (2011) 31, 439–447study, and Salford Royal NHS Foundation Trust for
funding the author and acting as sponsor for the
study. The authors are also grateful to the members
of the Independent Data Monitoring and Safety
Committee: Professor G Ford (Newcastle), Dr S Lane
(Liverpool), and Mr P Whitfield (Plymouth); and
the Trial Steering Committee: Professor A Burns
(Manchester), Professor D Crossman (Sheffield),
Professor C Moody (MRC), Mr A Vail (Salford),
Dr L Gregory (Sponsor representative), and Sandra
Buckley (BASIC, Salford). The authors also thank
Rachel Georgiou (Salford R&D), the patients who
kindly participated in this study, and the neuro-
surgical team at Hope Hospital for their support.
Disclosure/conflict of interest
The authors declare no conflict of interest.
References
Adams Jr HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L,
Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C,
Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser
RH, Scott PA, Wijdicks EF (2007) Guidelines for the
early management of adults with ischemic stroke:
a guideline from the American Heart Association/
American Stroke Association Stroke Council, Clinical
Cardiology Council, Cardiovascular Radiology and Inter-
vention Council, and the Atherosclerotic Peripheral
Vascular Disease and Quality of Care Outcomes
in Research Interdisciplinary Working Groups: The
American Academy of Neurology affirms the value of
this guideline as an educational tool for neurologists.
Circulation 115:e478–534
Arabi Y, Memish ZA, Balkhy HH, Francis C, Ferayan A,
Al Shimemeri A, Almuneef MA (2005) Ventri-
culostomy-associated infections: incidence and risk
factors. Am J Infect Control 33:137–43
Banks WA, Ortiz L, Plotkin SR, Kastin AJ (1991) Human
interleukin (IL) 1 alpha, murine IL-1 alpha and murine
IL-1 beta are transported from blood to brain in the
mouse by a shared saturable mechanism. J Pharmacol
Exp Ther 259:988–96
Banwell V, Sena ES, Macleod MR (2009) Systematic review
and stratified meta-analysis of the efficacy of inter-
leukin-1 receptor antagonist in animal models of stroke.
J Stroke Cerebrovasc Dis 18:269–76
Berrouane Y, Daudenthun I, Riegel B, Emery MN, Martin G,
Krivosic R, Grandbastien B (1998) Early onset pneumo-
nia in neurosurgical intensive care unit patients. J Hosp
Infect 40:275–80
Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry
VH, Styles P (2000) Interleukin-1beta -induced changes
in blood-brain barrier permeability, apparent diffusion
coefficient, and cerebral blood volume in the rat brain: a
magnetic resonance study. J Neurosci 20:8153–9
Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y,
Rothwell NJ (2001) Role of IL-1alpha and IL-1beta in
ischemic brain damage. J Neurosci 21:5528–34
Buttini M, Sauter A, Boddeke HW (1994) Induction of
interleukin-1 beta mRNA after focal cerebral ischaemia
in the rat. Brain Res Mol Brain Res 23:126–34
Cicala C, Cirino G (1998) Linkage between inflammation
and coagulation: an update on the molecular basis of the
crosstalk. Life Sci 62:1817–24
Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth
S, Georgiou R, Tyrrell PJ, Hopkins SJ, Rothwell NJ
(2008) Interleukin-1 receptor antagonist penetrates
human brain at experimentally therapeutic concen-
trations. J Cereb Blood Flow Metab 28:387–94
Deng YZ, Reeves MJ, Jacobs BS, Birbeck GL, Kothari RU,
Hickenbottom SL, Mullard AJ, Wehner S, Maddox K,
Majid A (2006) IV tissue plasminogen activator use in
acute stroke: experience from a statewide registry.
Neurology 66:306–12
Doczi T (1985) The pathogenetic and prognostic signi-
ficance of blood-brain barrier damage at the acute stage
of aneurysmal subarachnoid haemorrhage. Clinical and
experimental studies. Acta Neurochir (Wien) 77:110–32
Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den
Bergh WM, Vermeulen M, van Gijn J (2007) Calcium
antagonists for aneurysmal subarachnoid haemorrhage.
Cochrane Database Syst Rev; pp 1–50, CD000277
Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ,
Rothwell NJ, Tyrrell PJ (2005) A randomised phase II
study of interleukin-1 receptor antagonist in acute
stroke patients. J Neurol Neurosurg Psychiatry 76:
1366–72
Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell
NJ, Tyrrell PJ, Hopkins SJ, Rowland M (2008) Pharma-
cokinetic modelling of interleukin-1 receptor antagonist
in plasma and cerebrospinal fluid of patients following
subarachnoid haemorrhage. Br J Clin Pharmacol 65:
317–25
Gutierrez EG, Banks WA, Kastin AJ (1994) Blood-borne
interleukin-1 receptor antagonist crosses the blood-
brain barrier. J Neuroimmunol 55:153–60
Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K,
Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA
(1997) Inhibition of interleukin 1beta converting enzyme
family proteases reduces ischemic and excitotoxic
neuronal damage. Proc Natl Acad Sci USA 94:2007–12
Hawkins PN, Lachmann HJ, Aganna E, McDermott MF
(2004) Spectrum of clinical features in Muckle-Wells
syndrome and response to anakinra. Arthritis Rheum
50:607–12
Huang J, Upadhyay UM, Tamargo RJ (2006a) Inflammation
in stroke and focal cerebral ischemia. Surg Neurol
66:232–45
Huang P, Chen CH, Yang YH, Lin RT, Lin FC, Liu CK
(2006b) Eligibility for recombinant tissue plasminogen
activator in acute ischemic stroke: way to endeavor.
Cerebrovasc Dis 22:423–8
Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A,
Allen R, Harville T, Sun YN, Bevirt T, Aras G, Appleton
B (2009) Anakinra in the treatment of polyarticular-
course juvenile rheumatoid arthritis: safety and prelimi-
nary efficacy results of a randomized multicenter study.
Clin Rheumatol 28:129–37
Lacy CR, Suh DC, Bueno M, Kostis JB (2001) Delay in
presentation and evaluation for acute stroke: Stroke
Time Registry for Outcomes Knowledge and Epidemio-
logy (S.T.R.O.K.E.). Stroke 32:63–9
Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA,
Seifert B, Mandrup-Poulsen T, Donath MY (2007)
Interleukin-1-receptor antagonist in type 2 diabetes
mellitus. N Engl J Med 356:1517–26
Loddick SA, Rothwell NJ (1996) Neuroprotective effects of
human recombinant interleukin-1 receptor antagonist in
IL-1RA enters central nervous system within a therapeutic time window
J Galea et al
446
Journal of Cerebral Blood Flow & Metabolism (2011) 31, 439–447focal cerebral ischaemia in the rat. J Cereb Blood Flow
Metab 16:932–40
McMahon CJ, Smith D, Clark SR, Hulme S, Georgiou R,
Drake S, Selvarajah J, Hopkins SJ, Rothwell NJ, Tyrrell
PJ, King AT (2010) Delayed cerebral ischaemia after
subarachnoid haemorrhage: clinical predictors and
outcome. J Neurosurg (submitted)
Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA (2003)
Delayed administration of interleukin-1 receptor anta-
gonist protects against transient cerebral ischaemia in
the rat. Br J Pharmacol 140:471–6
Nuki G, Bresnihan B, Bear MB, McCabe D (2002) Long-term
safety and maintenance of clinical improvement following
treatment with anakinra (recombinant human interleukin-1
receptor antagonist) in patients with rheumatoid arthritis:
extension phase of a randomized, double-blind, placebo-
controlled trial. Arthritis Rheum 46:2838–46
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der
Worp BH, Howells DW (2006) 1,026 experimental
treatments in acute stroke. Ann Neurol 59:467–77
Obrenovitch TP, Zilkha E (1996) Inhibition of cortical
spreading depression by L-701,324, a novel antagonist
at the glycine site of the N-methyl-D-aspartate receptor
complex. Br J Pharmacol 117:931–7
Ogungbenro K, Graham G, Gueorguieva I, Aarons L (2005)
The use of a modified Fedorov exchange algorithm to
optimise sampling times for population pharmaco-
kinetic experiments. Comput Methods Programs
Biomed 80:115–25
Ohtsuki T, Ruetzler CA, Tasaki K, Hallenbeck JM (1996)
Interleukin-1 mediates induction of tolerance to global
ischemia in gerbil hippocampal CA1 neurons. J Cereb
Blood Flow Metab 16:1137–42
Rabinstein AA, Friedman JA, Weigand SD, McClelland RL,
Fulgham JR, Manno EM, Atkinson JL, Wijdicks EF
(2004) Predictors of cerebral infarction in aneurysmal
subarachnoid hemorrhage. Stroke 35:1862–6
Relton JK, Martin D, Thompson RC, Russell DA (1996)
Peripheral administration of interleukin-1 receptor
antagonist inhibits brain damage after focal cerebral
ischemia in the rat. Exp Neurol 138:206–13
Saver JL (2006) Time is brain—quantified. Stroke 37:263–6
Schneider SW, Gaubitz M, Luger TA, Bonsmann G (2007)
Prompt response of refractory Schnitzler syndrome
to treatment with anakinra. J Am Acad Dermatol 56:
S120–2
Seifert V, Trost HA, Stolke D (1990) Management mor-
bidity and mortality in grade IV and V patients with
aneurysmal subarachnoid haemorrhage. Acta Neurochir
(Wien) 103:5–10
STAIR (2001) Recommendations for clinical trial evalua-
tion of acute stroke therapies. Stroke 32:1598–606
Topakian R, Barrick TR, Howe FA, Markus HS (2010)
Blood-brain barrier permeability is increased in normal-
appearing white matter in patients with lacunar stroke
and leucoaraiosis. J Neurol Neurosurg Psychiatry
81:192–7
Topcuoglu MA, Singhal AB (2006) Effects of common
medications on cerebral vasospasm after subarachnoid
haemorrhage. Expert Opin Drug Saf 5:57–65
Yamasaki Y, Matsuura N, Shozuhara H, Onodera H,
Itoyama Y, Kogure K (1995) Interleukin-1 as a patho-
genetic mediator of ischemic brain damage in rats.
Stroke 26:676–80; discussion 81
This work is licensed under the Creative Com-
mons Attribution-NonCommercial-No Derivative
Works 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
IL-1RA enters central nervous system within a therapeutic time window
J Galea et al
447
Journal of Cerebral Blood Flow & Metabolism (2011) 31, 439–447